Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M183,251Revenue $M51,584Net Margin (%)42.7Z-Score2.5
Enterprise Value $M187,742EPS $3.2Operating Margin %30.5F-Score5
P/E(ttm))18.5Cash Flow Per Share $3.5Pre-tax Margin (%)30.5Higher ROA y-yN
Price/Book2.410-y EBITDA Growth Rate %3.1Quick Ratio2.4Cash flow > EarningsY
Price/Sales3.85-y EBITDA Growth Rate %9.0Current Ratio2.7Lower Leverage y-yN
Price/Cash Flow7.2y-y EBITDA Growth Rate %1.9ROA % (ttm)12.8Higher Current Ratio y-yY
Dividend Yield %3.5Insider Buy (3m)0ROE % (ttm)28.8Less Shares Outstanding y-yY
Payout Ratio %63.0Shares Outstanding M6,379ROI % (ttm)21.6Gross Margin Increase y-yN

Gurus Latest Trades with PFE

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PFEVanguard Health Care Fund 2014-06-30 Add0.62%$29.02 - $32.4
($30.05)
$ 28.89-4%Add 105.23%14,934,022
PFEJoel Greenblatt 2014-06-30 Add0.27%$29.02 - $32.4
($30.05)
$ 28.89-4%Add 71.59%1,741,314
PFECharles Brandes 2014-06-30 Add0.12%$29.02 - $32.4
($30.05)
$ 28.89-4%Add 5.78%6,075,460
PFERay Dalio 2014-06-30 Add0.06%$29.02 - $32.4
($30.05)
$ 28.89-4%Add 250.56%393,008
PFEMichael Price 2014-06-30 Reduce-0.97%$29.02 - $32.4
($30.05)
$ 28.89-4%Reduce -69.14%107,100
PFEDodge & Cox 2014-06-30 Reduce-0.5%$29.02 - $32.4
($30.05)
$ 28.89-4%Reduce -23.73%48,902,097
PFEJean-Marie Eveillard 2014-06-30 Reduce-0.47%$29.02 - $32.4
($30.05)
$ 28.89-4%Reduce -70.71%2,303,762
PFEJohn Hussman 2014-06-30 Sold Out -0.04%$29.02 - $32.4
($30.05)
$ 28.89-4%Sold Out0
PFEJoel Greenblatt 2014-03-31 Add0.38%$29.66 - $32.75
($31.39)
$ 28.89-8%Add 356.54%1,014,808
PFEJohn Hussman 2014-03-31 Buy 0.04%$29.66 - $32.75
($31.36)
$ 28.89-8%New holding, 17000 sh.17,000
PFEVanguard Health Care Fund 2014-03-31 Reduce-0.48%$29.66 - $32.75
($31.36)
$ 28.89-8%Reduce -40.13%7,276,622
PFEJean-Marie Eveillard 2014-03-31 Reduce-0.19%$29.66 - $32.75
($31.39)
$ 28.89-8%Reduce -22.77%7,866,473
PFEJean-Marie Eveillard 2013-12-31 Add0.16%$28.24 - $32.2
($30.7)
$ 28.89-6%Add 23.07%10,186,005
PFEJoel Greenblatt 2013-12-31 Add0.11%$28.24 - $32.2
($30.7)
$ 28.89-6%Add 241.71%222,280
PFERonald Muhlenkamp 2013-12-31 Add0.05%$28.24 - $32.2
($30.7)
$ 28.89-6%Add 29.15%45,129
PFERay Dalio 2013-12-31 Add0.01%$28.24 - $32.2
($30.7)
$ 28.89-6%Add 102.18%110,408
PFEVanguard Health Care Fund 2013-12-31 Reduce-0.91%$28.24 - $32.2
($30.7)
$ 28.89-6%Reduce -43.19%12,153,122
PFECharles Brandes 2013-12-31 Reduce-0.22%$28.24 - $32.2
($30.7)
$ 28.89-6%Reduce -9.32%5,767,402
PFEDavid Dreman 2013-12-31 Reduce-0.15%$28.24 - $32.2
($30.7)
$ 28.89-6%Reduce -85.73%10,163
PFEDonald Yacktman 2013-12-31 Sold Out -0.01%$28.24 - $32.2
($30.7)
$ 28.89-6%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PFE is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
PFE Ray Dalio 2014-06-30393,0080.010.09+250.56%
PFE Vanguard Health Care Fund 2014-06-3014,934,0220.231.2+105.23%
PFE Joel Greenblatt 2014-06-301,741,3140.030.65+71.59%
PFE David Dreman 2014-06-3013,61500.03+14.88%
PFE Charles Brandes 2014-06-306,075,4600.12.2+5.78%
PFE James Barrow 2014-06-3060,500,0580.952.4+1.01%
PFE Prem Watsa 2014-06-30235,00000.48
PFE Ruane Cunniff 2014-06-3010,98700-0.32%
PFE Ronald Muhlenkamp 2014-06-3041,01900.21-0.36%
PFE Mario Gabelli 2014-06-301,104,0700.020.17-5.28%
PFE John Keeley 2014-06-3089,83900.05-6.31%
PFE Dodge & Cox 2014-06-3048,902,0970.771.4-23.73%
PFE Michael Price 2014-06-30107,10000.39-69.14%
PFE Jean-Marie Eveillard 2014-06-302,303,7620.040.17-70.71%
PFE John Hussman 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


PFE: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
OLSON LAURIE JExecutive Vice President 2014-06-12Sell36,275$29.53-2view
Germano Geno JGroup President 2014-06-02Sell30,000$29.68-2.49view
YOUNG JOHN DGroup President 2014-03-17Sell9,000$31.38-7.78view
PFIZER INC10% Owner 2014-03-12Buy272,727$11163.09view
CANGIALOSI LORETTA VSr. Vice President, Controller 2014-03-04Sell102,943$32.05-9.7view
Dolsten MikaelPresident R&D 2014-03-04Sell35,789$32.58-11.17view
SUSMAN SALLYExecutive Vice President 2014-03-04Sell67,585$32.59-11.2view
PFIZER INC10% Owner 2014-02-04Buy227,261$8261.75view
DAMELIO FRANK AExecutive Vice President 2014-01-13Sell131,810$30.82-6.1view
DAMELIO FRANK AExecutive Vice President 2014-01-13Sell28,190$30.86-6.22view

Press Releases about PFE :

    Quarterly/Annual Reports about PFE:

      News about PFE:

      Articles On GuruFocus.com
      Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, MFG Aug 18 2014 
      A Strong Candidate for Investor´s Portfolios Aug 12 2014 
      Legendary Investor Irving Kahn's Top Five Stocks Aug 08 2014 
      Widely Held Guru Stocks Near 52-Week Lows Aug 05 2014 
      Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, UBS Aug 04 2014 
      Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
      Is Ken Fisher a Dividend Growth Investor? Jul 27 2014 
      Diamond Hill Capital Comments on Pfizer Inc Jul 25 2014 
      Dodge & Cox Second Quarter 2014 Commentary Jul 23 2014 
      Pfizer: A Fairly Valued Stock Jul 23 2014 


      More From Other Websites
      This stock may be hazardous to your financial health Aug 19 2014
      U.S. FDA approves Sanofi's Gaucher disease drug Cerdelga Aug 19 2014
      Pfizer Submits Palbociclib Marketing Application to the FDA Aug 19 2014
      The Negative Impact Of Pfizer's Mergers And Budget Cuts On Cancer R&D Aug 19 2014
      U.S. clears AstraZeneca over heart drug trial Aug 19 2014
      Pfizer Announces Submission of Palbociclib New Drug Application to the FDA Aug 18 2014
      Washington Post Off Base In Critiquing Pharma Efforts In Ebola Aug 18 2014
      Pfizer Announces Submission of Palbociclib New Drug Application to the FDA Aug 18 2014
      Premier Biotechnology & Anti-CTLA4 Aug 18 2014
      8:00 am Pfizer announces submission of Palbociclib NDA to the FDA Aug 18 2014
      Pfizer is Liable for Harm Caused by a Generic Version of its Drug: Court Aug 15 2014
      PFIZER INC Financials Aug 15 2014
      Digital Transformation Moves Pharma 'Beyond the Pill' Aug 15 2014
      Pfizer Announces FDA Acceptance Of And Priority Review Designation For Biologics License Application... Aug 14 2014
      Pfizer Announces FDA Acceptance Of And Priority Review Designation For Biologics License Application... Aug 14 2014
      Pfizer's Prevnar 13 Backed by U.S. Panel for Expanded Use Aug 14 2014
      [video] Pfizer and Merck Receive Key Regulatory Approvals Aug 14 2014
      [video] Howard Hughes, Pfizer Will Head Higher Says Becker Fund Manager Aug 14 2014
      U.S. judge lets investors pursue SAC insider trading lawsuit Aug 14 2014
      Why Pfizer (PFE) Stock Is Up Today Aug 14 2014

      Add Notes, Comments or Ask Questions

      User Comments

      SEENSCO
      ReplySEENSCO - 2 months ago
      PFE is trading at the low end of our short-term valuation range ($29-$36) and significantly below our Fair Value estimate of $42.41.
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK
      Email Hide